KimJ

J. Jekkie Kim

KimJ

J. Jekkie Kim

Partner

Palo Alto + 1 650 600 5133

Dr. Jekkie Kim advises life sciences and technology companies, as well as their investors and lenders on a broad range of matters. She has extensive experience advising clients on complex corporate business transactions, including those related to artificial intelligence and digital health, and focuses her practice on emerging companies and venture capital matters, strategic licensing and collaborations, and complex commercial transactions. 

While drawing upon her background as a medical doctor with clinical experience and her role as a member of the Institutional Review Board at Massachusetts General Hospital (now Mass General Brigham), Dr. Kim provides sophisticated and effective, yet practical, creative, and efficient strategies for her clients throughout their lifecycle.

Dr. Kim regularly speaks and writes on AI, digital health, healthcare, and life sciences related topics. She is an advisor to Stanford SPARK, a translational program that allows Stanford students and professors to generate drug and diagnostic proofs-of-concept for potential commercialization, using academic approaches combined with industry standards.

Prior to joining the firm, Dr. Kim was a partner at another international law firm.

Insights & News

View all of J. Jekkie's insights & news

Credentials

  • Education

    • JD, Boston University, 2008

    • MBA, Case Western Reserve University, 2008

    • LLM, Yonsei University Department of Medical Law and Ethics, 2003

    • MD, Yonsei University College of Medicine, 2003

  • Admissions

    • California

    • Massachusetts

    • New York

  • Languages

    • Korean

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel